REYON Pharmaceutical Co., Ltd. (KRX:102460)
South Korea
· Delayed Price · Currency is KRW 11,440
+20 (0.18%)
At close: Jun 18, 2025, 3:30 PM KST
REYON Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 148,043 | 148,300 | 151,071 | 154,039 | 142,801 | 130,034 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | - | - | -0 | Upgrade
|
| Revenue | 148,043 | 148,300 | 151,071 | 154,039 | 142,801 | 130,034 | Upgrade
|
| Revenue Growth (YoY) | -1.99% | -1.84% | -1.93% | 7.87% | 9.82% | -1.16% | Upgrade
|
| Cost of Revenue | 81,366 | 76,615 | 73,347 | 73,475 | 64,348 | 58,282 | Upgrade
|
| Gross Profit | 66,676 | 71,685 | 77,724 | 80,564 | 78,453 | 71,752 | Upgrade
|
| Selling, General & Admin | 63,427 | 64,138 | 64,306 | 66,286 | 63,151 | 61,008 | Upgrade
|
| Research & Development | 3,262 | 3,318 | 8,375 | 6,705 | 9,725 | 6,584 | Upgrade
|
| Other Operating Expenses | 1,001 | 1,046 | 981.05 | 942.46 | 958.94 | 884.68 | Upgrade
|
| Operating Expenses | 72,653 | 72,670 | 75,951 | 76,116 | 76,909 | 70,098 | Upgrade
|
| Operating Income | -5,976 | -985.46 | 1,773 | 4,448 | 1,545 | 1,654 | Upgrade
|
| Interest Expense | -4,476 | -1,253 | -195.53 | -122.2 | -111.19 | -178.01 | Upgrade
|
| Interest & Investment Income | 360.71 | 395.9 | 802.87 | 994.76 | 527.96 | 992.16 | Upgrade
|
| Earnings From Equity Investments | -4,283 | -4,359 | -960.18 | -1,968 | 1,684 | -475.29 | Upgrade
|
| Currency Exchange Gain (Loss) | 88.4 | 72.68 | 124.67 | -91.55 | 12.43 | 4.21 | Upgrade
|
| Other Non Operating Income (Expenses) | 19,281 | 11,217 | 4,938 | -945.79 | 514.97 | 430.31 | Upgrade
|
| EBT Excluding Unusual Items | 4,996 | 5,088 | 6,483 | 2,315 | 4,173 | 2,427 | Upgrade
|
| Gain (Loss) on Sale of Investments | 24.58 | 24.58 | -3,183 | 4,262 | 1,125 | 1,573 | Upgrade
|
| Gain (Loss) on Sale of Assets | 323.88 | 323.88 | 732.32 | 317.22 | 547.04 | 367.42 | Upgrade
|
| Other Unusual Items | -273.27 | -273.27 | - | - | - | - | Upgrade
|
| Pretax Income | 5,071 | 5,163 | 4,032 | 6,894 | 5,845 | 4,368 | Upgrade
|
| Income Tax Expense | 1,030 | 1,012 | 448.59 | -539.77 | 307.51 | 523.26 | Upgrade
|
| Earnings From Continuing Operations | 4,041 | 4,151 | 3,583 | 7,434 | 5,537 | 3,844 | Upgrade
|
| Net Income | 4,041 | 4,151 | 3,583 | 7,434 | 5,537 | 3,844 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 75 | 125 | - | Upgrade
|
| Net Income to Common | 4,041 | 4,151 | 3,583 | 7,359 | 5,412 | 3,844 | Upgrade
|
| Net Income Growth | 112.45% | 15.85% | -51.80% | 34.25% | 44.03% | -22.27% | Upgrade
|
| Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 18 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 | 17 | Upgrade
|
| Shares Change (YoY) | -0.80% | - | 0.46% | 3.03% | 4.05% | 1.01% | Upgrade
|
| EPS (Basic) | 220.33 | 226.34 | 195.38 | 414.51 | 305.44 | 225.75 | Upgrade
|
| EPS (Diluted) | 220.05 | 226.00 | 195.00 | 407.18 | 305.00 | 225.75 | Upgrade
|
| EPS Growth | 166.23% | 15.90% | -52.11% | 33.50% | 35.10% | -23.06% | Upgrade
|
| Free Cash Flow | -12,799 | -17,448 | -20,225 | -54,404 | -105,293 | -47,708 | Upgrade
|
| Free Cash Flow Per Share | -697.86 | -951.29 | -1102.71 | -2979.96 | -5942.30 | -2801.53 | Upgrade
|
| Dividend Per Share | - | - | 150.000 | 150.000 | 250.000 | 200.000 | Upgrade
|
| Dividend Growth | - | - | - | -40.00% | 25.00% | -41.71% | Upgrade
|
| Gross Margin | 45.04% | 48.34% | 51.45% | 52.30% | 54.94% | 55.18% | Upgrade
|
| Operating Margin | -4.04% | -0.66% | 1.17% | 2.89% | 1.08% | 1.27% | Upgrade
|
| Profit Margin | 2.73% | 2.80% | 2.37% | 4.78% | 3.79% | 2.96% | Upgrade
|
| Free Cash Flow Margin | -8.65% | -11.77% | -13.39% | -35.32% | -73.73% | -36.69% | Upgrade
|
| EBITDA | 7,242 | 5,358 | 6,555 | 8,981 | 6,210 | 6,219 | Upgrade
|
| EBITDA Margin | 4.89% | 3.61% | 4.34% | 5.83% | 4.35% | 4.78% | Upgrade
|
| D&A For EBITDA | 13,219 | 6,344 | 4,782 | 4,534 | 4,666 | 4,565 | Upgrade
|
| EBIT | -5,976 | -985.46 | 1,773 | 4,448 | 1,545 | 1,654 | Upgrade
|
| EBIT Margin | -4.04% | -0.66% | 1.17% | 2.89% | 1.08% | 1.27% | Upgrade
|
| Effective Tax Rate | 20.31% | 19.60% | 11.13% | - | 5.26% | 11.98% | Upgrade
|
| Advertising Expenses | - | 81.74 | 76.91 | 106.09 | 56.01 | 152.9 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.